Clinical Trial Update: A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety and tolerability of RCT2100, a CFTR mRNA therapy, in healthy participants and people with cystic fibrosis, is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• RCT2100 (CFTR mRNA)

Snippet

Sponsor: ReCode Therapeutics | Conditions: Cystic Fibrosis | Phase 2 | Status: RECRUITING